Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes | Zendy

Gunnar Gislason | Zendy; Jeppe Nørgaard Rasmussen | Zendy; Steen Z. Abildstrøm | Zendy; Tina Ken Schramm | Zendy; Morten Lock Hansen | Zendy; Pernille Buch | Zendy; Rikke Sørensen | Zendy; Fredrik Folke | Zendy; Niels Gadsbøll | Zendy; Søren Rasmussen | Zendy; Lars Køber | Zendy; Mette Madsen | Zendy; Christian TorpPedersen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes

Author(s) -

Gunnar Gislason,

Jeppe Nørgaard Rasmussen,

Steen Z. Abildstrøm,

Tina Ken Schramm,

Morten Lock Hansen,

Pernille Buch,

Rikke Sørensen,

Fredrik Folke,

Niels Gadsbøll,

Søren Rasmussen,

Lars Køber,

Mette Madsen,

Christian TorpPedersen

Publication year - 2007

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.669101

Subject(s) - medicine , spironolactone , dose , heart failure , pharmacotherapy , hazard ratio , ramipril , cardiology , pharmacology , blood pressure , confidence interval

Undertreatment with recommended pharmacotherapy is a common problem in heart failure and may influence prognosis. We studied initiation and persistence of evidence-based pharmacotherapy in 107,092 patients discharged after first hospitalization for heart failure in Denmark from 1995 to 2004.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research